Phaseline

Companies › EMS

EMS: clinical trials, targets and expected readouts

6 active drug programs in 6 registered trials: 6 Phase 3; Metabolic and endocrine, Immunology, Genitourinary, Neurology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CDE100 association–Phase 3Primary DysmenorrheaJan 2027
MADALENA ASSOCIATION–Phase 3Type 2 Diabetes MellitusJun 2027
BERLIM 25/20 ASSOCIATION
SGLT2 inhibitor (empagliflozin 25 mg) combined with HMG-CoA reductase inhibitor (rosuvasta
SGLT2, LDLRPhase 3Dyslipidemia Associated With Type II Diabetes MellitusSep 2027
Finlândia Association–Phase 3Androgenetic AlopeciaSep 2027
Piemonte association
unclear - multi-component drug association for type 2 diabetes
–Phase 3Type II DiabetesSep 2027
Praga formulation
Voltage-gated calcium channel modulator
–Phase 3Neuropathic Pain–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04666714Praga formulationPhase 3Neuropathic PainNeurologySep 2025
NCT05640232CDE100 associationPhase 3Primary DysmenorrheaGenitourinaryJan 2027
NCT04670666MADALENA ASSOCIATIONPhase 3Type 2 Diabetes MellitusMetabolic and endocrineJun 2027
NCT04594018Finlândia AssociationPhase 3Androgenetic AlopeciaImmunologySep 2027
NCT04602754BERLIM 25/20 ASSOCIATIONPhase 3Dyslipidemia Associated With Type II Diabetes MellitusMetabolic and endocrineSep 2027
NCT05028140Piemonte associationPhase 3Type II DiabetesMetabolic and endocrineSep 2027

Targets

SGLT2 (1) LDLR (1)

Companies with the same targets

–

Companies built like this

Gan & Lee Pharmaceuticals. Fresenius Kabi Renibus Therapeutics Azafaros Kowa Company

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.